Hypertension and diabetes treatment affordability and government expenditures following changes in patient cost sharing in the "Farmácia popular" program in Brazil: an interrupted time series study.
Isabel Cristina Martins EmmerickMônica Rodrigues CamposRondineli Mendes da SilvaLuisa Arueira ChavesAndréa Dâmaso BertoldiDennis Ross-DegnanVera Lucia LuizaPublished in: BMC public health (2020)
FP rapidly increased its coverage in terms of both program reach and proportion of cost subsidized during the period analyzed. Costs of individual HTN and DM treatments in FP were reduced after 2011 for both patients (free) and government (better negotiated prices). However, overall FP expenditures by MoH increased due to markedly increased utilization. The FP is sustainable as a complementary policy but cannot feasibly substitute for the distribution of medicines by the SUS.
Keyphrases
- end stage renal disease
- quality improvement
- blood pressure
- newly diagnosed
- type diabetes
- ejection fraction
- healthcare
- cardiovascular disease
- public health
- prognostic factors
- health insurance
- mental health
- glycemic control
- peritoneal dialysis
- health information
- patient reported outcomes
- weight loss
- combination therapy
- replacement therapy